DOCS Stock Analysis: Doximity | NYSE
Health Information Services | NYSE, USA | Market Cap: 4.454m USD | 12M Return: -59.5% | US26622P1075 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 105M
EPS Trend: 90.9%
Qual. Beats: 0
Rev. Trend: 99.2%
Qual. Beats: 1
Warnings
Tailwinds
No distinct edge detected
Seasonality 5.1 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Doximity, Inc. operates a digital platform for U.S. medical professionals, offering a personalized newsfeed with clinical content, peer updates, and sponsored material from pharmaceutical manufacturers and health systems. The company provides workflow tools such as Ask (a HIPAA-compliant AI assistant), Scribe (AI-powered clinical documentation), Telehealth, and AMiON (on-call scheduling). Its customer base includes physicians, nurse practitioners, physician assistants, medical students, pharmaceutical manufacturers, and healthcare systems. Originally incorporated as 3MD Communications, Inc., the company rebranded to Doximity in June 2010 and is headquartered in San Francisco, California.
Within the Health Care Technology sub-industry, Doximity functions as a professional networking and SaaS-style platform, monetizing through subscriptions sold to healthcare systems and pharmaceutical marketing services. The company is listed on the NYSE under the ticker DOCS and went public in June 2021.
- AI Scribe and Ask tools drive average revenue per user higher
- Pharma manufacturer marketing budgets pressure subscription renewal growth
- Abridge and Suki competition intensifies in clinical AI documentation market
| Net Income: 167.0m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.28 > 0.02 and ΔFCF/TA 3.76 > 1.0 |
| NWC/Revenue: 116.5% < 20% (prev 148.3%; Δ -31.80% < -1%) |
| CFO/TA 0.28 > 3% & CFO 306.3m > Net Income 167.0m |
| Net Debt (-678.1m) to EBITDA (243.8m): -2.78 < 3 |
| Current Ratio: 6.08 > 1.5 & < 3 |
| Outstanding Shares: last quarter (191.2m) vs 12m ago -4.97% < -2% |
| Gross Margin: 88.07% > 18% (prev 90.14%; Δ -2.08% > 0.5%) |
| Asset Turnover: 57.30% > 50% (prev 48.95%; Δ 8.34% > 0%) |
| Interest Coverage Ratio: error (cannot be calculated; needs correct EBIT TTM and Interest Expense TTM) |
| A: 0.70 (Total Current Assets 914.0m - Total Current Liabilities 150.4m) / Total Assets 1.08b |
| B: -0.11 (Retained Earnings -119.0m / Total Assets 1.08b) |
| C: 0.20 (EBIT TTM 226.2m / Avg Total Assets 1.14b) |
| D: 5.46 (Book Value of Equity 916.1m / Total Liabilities 167.8m) |
| Altman-Z'' = 11.33 = AAA |
| DSRI: 1.13 (Receivables 177.6m/141.7m, Revenue 655.6m/589.6m) |
| GMI: 1.02 (GM 90.14% / 88.07%) |
| AQI: 1.08 (AQ_t 0.13 / AQ_t-1 0.12) |
| SGI: 1.11 (Revenue 655.6m / 589.6m) |
| TATA: -0.13 (NI 167.0m - CFO 306.3m) / TA 1.08b) |
| Beneish M = -2.78 (Cap -4..+1) = A |
As of August 20, 2026, the stock is trading at USD 25.75 with a total of 4,900,382 shares traded. Over the past week, the price has changed by +3.04%, over one month by +18.50%, over three months by +33.70% and over the past year by -59.52%.
Current recommended Stop Loss: 23.40 (which is 9.1% or 1.2 ATR below the current price).
Doximity has received a consensus analysts rating of 3.68. Therefore, it is recommended to hold DOCS.
- StrongBuy: 5
- Buy: 3
- Hold: 11
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 29.4 | 14.2% |
P/E Trailing = 31.2375
P/E Forward = 19.4175
P/S = 6.7947
P/B = 5.0804
P/EG = 0.5895
Revenue TTM = 655.6m USD
EBIT TTM = 226.2m USD
EBITDA TTM = 243.8m USD
Long Term Debt = 7.53m USD (estimated: total debt 9.67m - short term 2.14m)
Short Term Debt = 2.14m USD (from shortTermDebt, last quarter)
Debt = 9.67m USD (from shortLongTermDebtTotal, last quarter) (leases 9.67m already included)
Net Debt = -678.1m USD (calculated: Debt 9.67m - CCE 687.8m)
Enterprise Value = 3.78b USD (4.45b + Debt 9.67m - CCE 687.8m)
Interest Coverage Ratio = unknown (Ebit TTM 226.2m / Interest Expense TTM 0.0)
EV/FCF = 12.62x (Enterprise Value 3.78b / FCF TTM 299.3m)
FCF Yield = 7.93% (FCF TTM 299.3m / Enterprise Value 3.78b)
FCF Margin = 45.65% (FCF TTM 299.3m / Revenue TTM 655.6m)
Net Margin = 25.48% (Net Income TTM 167.0m / Revenue TTM 655.6m)
Gross Margin = 88.07% ((Revenue TTM 655.6m - Cost of Revenue TTM 78.2m) / Revenue TTM)
Gross Margin QoQ = 84.87% (prev 86.65%)
Tobins Q-Ratio = 3.48 (Enterprise Value 3.78b / Total Assets 1.08b)
Interest Expense / Debt = 0.0% (Interest Expense 0.0 / Debt 9.67m)
Taxrate = 26.16% (59.2m / 226.2m)
NOPAT = 167.0m (EBIT 226.2m * (1 - 26.16%))
Current Ratio = 6.08 (Total Current Assets 914.0m / Total Current Liabilities 150.4m)
Debt / Equity = 0.01 (Debt 9.67m / totalStockholderEquity, last quarter 916.1m)
Debt / EBITDA = -2.78 (Net Debt -678.1m / EBITDA 243.8m)
Debt / FCF = -2.27 (Net Debt -678.1m / FCF TTM 299.3m)
Total Stockholder Equity = 985.4m (last 4 quarters mean from totalStockholderEquity)
RoA = 14.60% (Net Income 167.0m / Total Assets 1.08b)
RoE = 16.95% (Net Income TTM 167.0m / Total Stockholder Equity 985.4m)
RoCE = 22.78% (EBIT 226.2m / Capital Employed (Equity 985.4m + L.T.Debt 7.53m))
RoIC = 18.50% (NOPAT 167.0m / Invested Capital 902.8m)
WACC = 10.33% (E(4.45b)/V(4.46b) * Re(10.35%) + D(9.67m)/V(4.46b) * Rd(0.0%) * (1-Tc(0.26)))
Discount Rate = 10.35% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: -66.81 | Cagr: -2.23%
[DCF] Terminal Value 69.46% ; FCFF base≈294.5m ; Y1≈305.9m ; Y5≈346.8m
[DCF] Fair Price = 36.74 (EV 4.00b - Net Debt -678.1m = Equity 4.68b / Shares 127.3m; r=10.33% [WACC]; 5y FCF grow 4.16% → 2.50% )
EPS Correlation: 90.93 | EPS CAGR: 23.06% | SUE: -0.42 | # QB: 0
Revenue Correlation: 99.16 | Revenue CAGR: 16.14% | SUE: 0.96 | # QB: 1
EPS current Quarter (2026-09-30): EPS=0.35 | Chg30d=-5.41% | Revisions=+0% | Analysts=16
EPS next Quarter (2026-12-31): EPS=0.42 | Chg30d=-5.17% | Revisions=+40% | Analysts=16
EPS current Year (2027-03-31): EPS=1.36 | Chg30d=-4.98% | Revisions=+0% | GrowthEPS=-10.3% | GrowthRev=+4.9%
EPS next Year (2028-03-31): EPS=1.56 | Chg30d=-2.23% | Revisions=-71% | GrowthEPS=+14.3% | GrowthRev=+6.5%
[Analyst] Revisions Ratio: -43% (up=5, down=15)